Find HDV and Determine Its Status in Turkey

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorYaşar Bayındır, MD

About this trial

The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV/HCV and to detect liver fibrosis with a non-invasive method.

Eligibility criteria

Qualifiers

Adults (Age≥18)

Being HBsAg positive for at least six months

Being a citizen of the Republic of Türkiye

Disqualifiers

There are no exclusion criteria in this study.

Trial design

Treatments tested in this trial

  • Anti Delta

Treatment groups

20,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Yaşar Bayındır, MD

Lead sponsor

Guven Health Group

Sponsor institution

SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY

Collaborator

Gilead Sciences

Collaborator